Zacks Investment Research cut shares of Ra Pharmaceuticals (NASDAQ:RARX) from a hold rating to a sell rating in a report released on Tuesday morning.

According to Zacks, “Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

Several other analysts have also commented on RARX. ValuEngine lowered Ra Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, October 16th. BidaskClub upgraded Ra Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, October 19th. Credit Suisse Group set a $25.00 price objective on Ra Pharmaceuticals and gave the company a buy rating in a research report on Friday, October 19th. Finally, BMO Capital Markets set a $34.00 price objective on Ra Pharmaceuticals and gave the company a buy rating in a research report on Monday, December 10th. One research analyst has rated the stock with a sell rating, five have issued a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and an average target price of $29.00.

NASDAQ RARX traded down $0.78 during trading on Tuesday, reaching $19.95. 7,378 shares of the company’s stock were exchanged, compared to its average volume of 544,331. Ra Pharmaceuticals has a fifty-two week low of $4.78 and a fifty-two week high of $23.90. The firm has a market capitalization of $700.12 million, a PE ratio of -8.31 and a beta of 0.82.

Ra Pharmaceuticals (NASDAQ:RARX) last issued its quarterly earnings data on Wednesday, November 7th. The company reported ($0.51) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.49) by ($0.02). On average, equities research analysts forecast that Ra Pharmaceuticals will post -2.11 EPS for the current fiscal year.

In other news, major shareholder Enterprise Associates 13 L. New bought 645,161 shares of the company’s stock in a transaction dated Friday, December 14th. The stock was bought at an average price of $15.50 per share, for a total transaction of $9,999,995.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Rajeev M. Shah bought 1,006,452 shares of the company’s stock in a transaction dated Friday, December 14th. The shares were purchased at an average price of $15.50 per share, with a total value of $15,600,006.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 2,658,065 shares of company stock valued at $41,200,008. 11.40% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc boosted its holdings in shares of Ra Pharmaceuticals by 9.1% during the 3rd quarter. Vanguard Group Inc now owns 739,337 shares of the company’s stock valued at $13,374,000 after acquiring an additional 61,929 shares in the last quarter. Federated Investors Inc. PA bought a new position in Ra Pharmaceuticals during the 3rd quarter worth $65,000. Vanguard Group Inc. raised its position in Ra Pharmaceuticals by 9.1% during the 3rd quarter. Vanguard Group Inc. now owns 739,337 shares of the company’s stock worth $13,374,000 after purchasing an additional 61,929 shares during the last quarter. TIAA CREF Investment Management LLC raised its position in Ra Pharmaceuticals by 289.7% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 280,761 shares of the company’s stock worth $5,079,000 after purchasing an additional 208,720 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new position in Ra Pharmaceuticals during the 3rd quarter worth $1,415,000. Institutional investors own 74.74% of the company’s stock.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Featured Story: Coverage Ratio

Get a free copy of the Zacks research report on Ra Pharmaceuticals (RARX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.